GKWIM
CUE icon

Gerber Kawasaki Wealth & Investment Management’s Cue Biopharma CUE Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7
Closed -$2K – 462
2021
Q3 		$2K Buy
+7
New +$2.44K ﹤0.01% 881

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's CUE Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Cue Biopharma (CUE) in Q4 2021, closing a stake of 7 shares — an estimated $2K sold.

Gerber Kawasaki Wealth & Investment Management first reported a position in CUE in Q3 2021 and held it in 1 quarter. The position peaked at $2K in Q3 2021. 90 funds tracked by Wall St. Rank hold CUE as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Cue Biopharma position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 7 Cue Biopharma shares in Q4 2021, an estimated $2K.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Cue Biopharma in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's Cue Biopharma position peaked at $2K in Q3 2021.
  • 90 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.